Form 4: Charles River Laboratories Director Mark Enyedy Acquires Company Stock and Options

Mark J. Enyedy, a Director at Charles River Laboratories International, Inc., acquired 946 shares of common stock and 2,082 stock options on June 2, 2025, as part of a compensation grant.

Summary

• Mark J. Enyedy, a Director of Charles River Laboratories International, Inc. (CRL), reported transactions on June 2, 2025.
• He acquired 946 shares of Common Stock at a price of $135.04 per share. These are unvested restricted stock units (RSUs) that will vest upon the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• He also acquired 2,082 Stock Options (Right to Buy) with an exercise price of $135.04 per share. These options become exercisable upon the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders, and expire on June 2, 2035.
• Following these transactions, Mr. Enyedy beneficially owns 946 shares of Common Stock (unvested RSUs) and 2,082 Stock Options directly.

Sentiment

Score: 7

Explanation: The filing reports a routine insider equity grant, which is generally a neutral to slightly positive signal as it aligns management's interests with shareholders. There are no negative financial implications or red flags within the document itself.

Positives

• The acquisition of company stock and options by a director indicates alignment of interests with shareholders.
• The grants are likely part of a long-term incentive compensation plan, which can motivate management performance and retention.

Risks

• The value of the acquired shares and options is subject to the future performance of Charles River Laboratories' stock price.
• Unvested restricted stock units and stock options carry the risk of forfeiture if vesting conditions (e.g., continued employment) are not met.

Future Outlook

This Form 4 filing primarily reports past transactions (as of the transaction date) and future vesting/exercisability dates for equity grants. It does not provide a general future outlook for the company's financial performance or strategic direction.

Industry Context

This filing is a routine insider transaction report, common across all publicly traded companies. It reflects standard executive compensation practices involving equity grants, which are prevalent in the life sciences and pharmaceutical services industry where Charles River Laboratories operates, to align executive incentives with long-term shareholder value.

Comparison to Industry Standards

• The granting of restricted stock units (RSUs) and stock options at market price as part of executive compensation is a common practice across industries, including the life sciences sector.
• Companies like LabCorp (LH) or IQVIA (IQV), which operate in similar contract research or laboratory services, often utilize similar equity-based compensation structures for their directors and executives to incentivize long-term performance and retention.
• The vesting schedule (one year or next annual meeting) for RSUs and options is typical for such grants, balancing retention with performance incentives.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to better long-term performance.

Next Steps

• Vesting of 946 restricted stock units on the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Stock options for 2,082 shares become exercisable on the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Mark J Enyedy